HDAMM-predictor: prediction of progression in asymptomatic myeloma patientshttps://doi.org/10.11588/data/10092Rème, ThierryEmde, MartinaSeckinger, AnjaHose, DirkheiDATA2016-10-282017-04-05T09:33:38ZThe HDAMM-predictor is based on microarray gene expression and predicts the risk of progression from asymptomatic to symptomatic myeloma. It divides the patients in three groups, from low to high risk to progress. It was generated according to the method published by Rème et al. 2013. Gene expression profiles of 259 asymptomatic myeloma patients were used as trainingset.Medicine, Health and Life SciencesMultiple myelomaRisk predictionAsymptomatic myelomaProgressionPrognosisSeckinger A, Jauch A, Emde M, Beck S, Mohr M, Granzow M, Hielscher T, Rème T, Schnettler R, Fard N, Hinderhofer K, Pyl P T, Huber W, Benes V, Marciniak-Czochra A, Pantesco V, Ho A D, Klein B, Goldschmidt H, Hillengass J, Hose D. Asymptomatic Multiple Myeloma - (Molecular) Background of Progression, Evolution and Prognosis. Manuscript under review.Seckinger A, Jauch A, Emde M, Beck S, Mohr M, Granzow M, Hielscher T, Rème T, Schnettler R, Fard N, Hinderhofer K, Pyl P T, Huber W, Benes V, Marciniak-Czochra A, Pantesco V, Ho A D, Klein B, Goldschmidt H, Hillengass J, Hose D. Asymptomatic Multiple Myeloma - (Molecular) Background of Progression, Evolution and Prognosis. Manuscript under review.Rème T, Hose D, Theillet C, Klein B. Modeling risk stratification in human cancer. Bioinformatics 2013;29:1149-57., doi, 10.1093/bioinformatics/btt124, http://dx.doi.org/10.1093/bioinformatics/btt1242016-022016-10-26Licensed under GNU General Public License version 3, <a href="http://www.gnu.org/licenses/gpl">http://www.gnu.org/licenses/gpl</a>